(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

AMTYMSO

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

AMTYMSO

ST13

US500000099222190

Class

5, 10

Filing

99222190

Registration

8108489

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

23

Latest update

01/20/2026

Classification

Registered

Trademark type

Word

Nice classes

5, 10

Filing date

06/06/2025

Registration date

01/20/2026

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

01/20/2026

Last transaction

01/20/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Foreign priority

Drawing code

4

Owner type

65

Owner location

Valby, DK

Examiner

NKOJO,RHODA K

Law office

M80

Current location

FILE REPOSITORY (FRANCONIA)

Holders and representatives

Holders

H. Lundbeck A/S

Representatives

Maren Perry KING & SPALDING LLP

Technical classification

Nice Classes

Class 5Class 10

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Sanitary preparations for medical purposes; dietetic preparations adapted for medical purposes; vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases ofgenerated from and affecting the central nervous system; pharmaceutical preparations and substances for treatment of central nervous system disorders; central nervous system stimulants; pharmaceutical preparations and substances for the diagnosisprevention and treatment of psychiatricneurologicalneurohormonalneurogeneticneuroendocrinological and autoimmune diseases and disorders; pharmaceutical preparations and substances for diagnosisprevention and treatment of dementiaAlzheimer's diseasedepressionpsychosisanxietyLennox-Gastaut diseaseepilepsyDravet SyndromeDevelopmental and Epileptic Encephalopathy (DEE)alpha-synucleinopathiesMultiple System Atrophy (MSA)dementia with Lewy bodiesrapid eye movement (REM) sleep behavior syndromeporphyriaHuntington's diseaseinsomniaParkinson's diseasesclerosismultiple sclerosisschizophreniabipolar disordercancerpainmigraineheadacheHorton's headachetraumatic brain injurypost-traumatic brain injurydizzinessseizuresstrokecognitive impairmentcognitive disorders and diseasesmood disordersfallsmovement disorders and diseasestremoragitationmaniaaggressionautismmelancholiaObsessive Compulsive Disorder (OCD)Tourette's syndromerestlessnessakathisiafatiguesomnolencenauseaCushing's diseaseAdrenogenital syndrome (AGS)narcolepsyPost-Traumatic Stress Disorder (PTSD)Attention Deficit Hyperactivity Disorder (ADHD)Progressive Supranuclear Palsy (PSP)Thyroid Associated Orbitopathy (TAO)Graves OrbitopathyHashimoto's Thyroiditisalcoholism and addiction; diagnostic agents and preparations for medical purposes; chemical substances for diagnostic and medical purposeschemical reagents for medical usediagnostic chemical reagents for medical purposes; medical diagnostic reagents

Class 10

Medical apparatusinfusion and injection devices for administering drugs; syringesintravenous bags sold empty for intravenous therapyintravenous (IV) feeding tubesintravenous (IV) infusion pumpsintravenous (IV) catheters; injection devices for administering drugssyringes and needles for injections and medical purposes; apparatus and instruments for diagnostic purposesdosage management dispensers for medicines and containing downloadable and recorded software for medical information management for use in web-based physical and psychological examination and assessment of patients at a distance and at a clinic; medical devices and instruments for the diagnosisadministrationmonitoringassessmentcontrol and examination of psychiatricneurologicalneurohormonalneurogeneticneuroendocrinological and autoimmune disorders and diseases; integrated medical systems comprising of medical instruments for diagnostics and examination of patients and downloadable computer software for processing patient intake and communications and information managementall for use in the physical and psychological and neurological examination and assessment of patients and clients; integrated medical systems comprised of medical devices and instruments for treating central nervous system diseases and disorders and psychiatricneurologicalneurohormonalneurogeneticneuroendocrinological and autoimmune disorders and diseasesall for the purposes of managementmeasurementmonitoringevaluationcontrolcollectionstoragetransmission and examination of patient and client data and information; medical instruments for providing medication administering informationguidancemanagement in the nature of devices for delivery and administering of medicines and infusion pumps

Publications

History of USPTO decisions and trademark events.

23 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

01/20/2026

R.PR

REGISTERED-PRINCIPAL REGISTER

01/20/2026

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

12/02/2025

PUBO

PUBLISHED FOR OPPOSITION

12/02/2025

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

11/26/2025

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

11/05/2025

XAEC

EXAMINER'S AMENDMENT ENTERED

11/05/2025

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

11/05/2025

GNEA

EXAMINERS AMENDMENT E-MAILED

11/05/2025

CNEA

EXAMINERS AMENDMENT -WRITTEN

11/05/2025

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

11/03/2025

GNFR

FINAL REFUSAL E-MAILED

11/03/2025

CNFR

FINAL REFUSAL WRITTEN

11/03/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

09/24/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

09/24/2025

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

09/24/2025

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

06/28/2025

GNRT

NON-FINAL ACTION E-MAILED

06/28/2025

CNRT

NON-FINAL ACTION WRITTEN

06/28/2025

DOCK

ASSIGNED TO EXAMINER

06/24/2025

MAFR

APPLICATION FILING RECEIPT MAILED

06/06/2025

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

06/06/2025

NWAP

NEW APPLICATION ENTERED

06/06/2025

Continuous trademark protection

Get notified about every new filing that threatens AMTYMSO or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.